Compare VRTX & CVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | CVS |
|---|---|---|
| Founded | 1989 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Retail-Drug Stores and Proprietary Stores |
| Sector | Technology | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 100.7B |
| IPO Year | 2006 | 1994 |
| Metric | VRTX | CVS |
|---|---|---|
| Price | $480.99 | $78.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 18 |
| Target Price | ★ $526.79 | $94.33 |
| AVG Volume (30 Days) | 1.3M | ★ 7.7M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.49% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | 1.39 |
| Revenue | $2,488,652,000.00 | ★ $402,067,000,000.00 |
| Revenue This Year | $11.10 | $2.53 |
| Revenue Next Year | $10.23 | $4.78 |
| P/E Ratio | ★ $31.52 | $54.81 |
| Revenue Growth | ★ 46.20 | 7.85 |
| 52 Week Low | $362.50 | $58.35 |
| 52 Week High | $519.68 | $85.15 |
| Indicator | VRTX | CVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 53.09 |
| Support Level | $432.09 | $76.72 |
| Resistance Level | $484.17 | $80.76 |
| Average True Range (ATR) | 13.51 | 2.37 |
| MACD | 0.60 | 0.09 |
| Stochastic Oscillator | 50.38 | 80.44 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.